Advantage Investment Management’s Neurocrine Biosciences NBIX Stock Holding History

Advantage Investment Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$14K	Hold	150	–	–	0.01%	597
2019 Q2	$13K	Hold	150	–	–	0.01%	622
2019 Q1	$13K	Hold	150	–	–	0.01%	613
2018 Q4	$11K	Hold	150	–	–	0.01%	636
2018 Q3	$18K	Hold	150	–	–	0.01%	597
2018 Q2	$15K	Hold	150	–	–	0.01%	595
2018 Q1	$12K	Hold	150	–	–	﹤0.01%	647
2017 Q4	$12K	Sell	150 -20	-12%	-$1.36K	﹤0.01%	658
2017 Q3	$10K	Hold	170	–	–	﹤0.01%	689
2017 Q2	$8K	Buy	170 +20	+13%	+$970	﹤0.01%	750
2017 Q1	$7K	Hold	150	–	–	﹤0.01%	754
2016 Q4	$6K	Hold	150	–	–	﹤0.01%	722
2016 Q3	$8K	Sell	150 -40	-21%	-$1.99K	﹤0.01%	658
2016 Q2	$9K	Buy	190 +40	+27%	+$1.84K	﹤0.01%	610
2016 Q1	$6K	Hold	150	–	–	﹤0.01%	660
2015 Q4	$8K	Hold	150	–	–	﹤0.01%	608
2015 Q3	$6K	Buy	+150	New	+$7.25K	﹤0.01%	630

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Advantage Investment Management's NBIX Position: Q3 2019 in Review

Advantage Investment Management held its Neurocrine Biosciences (NBIX) position steady in Q3 2019 at 150 shares worth $14K. The position accounts for 0.01% of the portfolio, ranked #597.

Advantage Investment Management first reported a position in NBIX in Q3 2015 and has held it in 17 quarters since. The position peaked at $18K in Q3 2018. 333 funds tracked by Wall St. Rank hold NBIX as of Q3 2019.

Advantage Investment Management held 150 shares of Neurocrine Biosciences worth $14K as of Q3 2019.
Advantage Investment Management left its Neurocrine Biosciences share count unchanged in Q3 2019.
Neurocrine Biosciences made up 0.01% of Advantage Investment Management's portfolio in Q3 2019, its #597 holding.
Advantage Investment Management first reported a position in Neurocrine Biosciences in Q3 2015 and has held it in 17 quarters since.
Advantage Investment Management's Neurocrine Biosciences position peaked at $18K in Q3 2018.
333 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2019.

Based on Advantage Investment Management's 13F filing for Q3 2019, filed 8 Oct 2019.